Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propentofylline is a methylated xanthine compound that functions as a phosphodiesterase inhibitor and an adenosine reuptake blocker. It exhibits neuroprotective and anti-inflammatory properties by diminishing the activation of microglial cells and astrocytes. The drug also improves thiol-based antioxidant defenses through the induction of glutathione reductase activity and inhibits mitogen-activated protein kinase p38. It has been investigated for various conditions, including vascular cognitive impairment, Alzheimer's disease, irritability associated with autism spectrum disorder, postoperative pain, and positive symptoms of schizophrenia. Additionally, it is used in veterinary medicine for feline infectious peritonitis and canine cognitive dysfunction, and has shown effects on amyloid-beta processing and aggregation, as well as cholesterol levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Propentofylline.